National Bank of Canada’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

National Bank of Canada’s Portfolio STAB Stock Details STAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,000	Closed	-$81	–	2950
2022 Q4	$81	Hold	1,000	–	–	﹤0.01%	2721
2022 Q3	$0	Hold	1,000	–	–	﹤0.01%	2966
2022 Q2	$0	Hold	1,000	–	–	﹤0.01%	3074
2022 Q1	$0	Buy	1,000 +500	+100%	+$535	﹤0.01%	3091
2021 Q4	$1K	Buy	+500	New	+$1.48K	﹤0.01%	2792

Other funds holding STAB

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TAM

Tucker Asset Management Littleton, Colorado $343M AUM 17.55% 1-Year Est. Return

National Bank of Canada's STAB Position: Q1 2023 in Review

National Bank of Canada sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2023, closing a stake of 1,000 shares — an estimated $81 sold.

National Bank of Canada first reported a position in STAB in Q4 2021 and held it in 5 quarters. The position peaked at $1K in Q4 2021. 4 funds tracked by Wall St. Rank hold STAB as of Q1 2023.

National Bank of Canada reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
National Bank of Canada sold 1,000 Statera Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $81.
National Bank of Canada first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
National Bank of Canada's Statera Biopharma, Inc. Common Stock position peaked at $1K in Q4 2021.
4 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2023.

Based on National Bank of Canada's 13F filing for Q1 2023, filed 12 Apr 2023.